-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Coherus BioSciences (NASDAQ:CHRS) Three-year Losses Have Grown Faster Than Shareholder Returns Have Fallen, but the Stock Ascends 6.1% This Past Week
Coherus BioSciences (NASDAQ:CHRS) Three-year Losses Have Grown Faster Than Shareholder Returns Have Fallen, but the Stock Ascends 6.1% This Past Week
This month, we saw the Coherus BioSciences, Inc. (NASDAQ:CHRS) up an impressive 43%. But that doesn't change the fact that the returns over the last three years have been less than pleasing. After all, the share price is down 46% in the last three years, significantly under-performing the market.
While the last three years has been tough for Coherus BioSciences shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.
See our latest analysis for Coherus BioSciences
Coherus BioSciences isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
Over the last three years, Coherus BioSciences' revenue dropped 10% per year. That is not a good result. The stock has disappointed holders over the last three years, falling 13%, annualized. And with no profits, and weak revenue, are you surprised? However, in this kind of situation you can sometimes find opportunity, where sentiment is negative but the company is actually making good progress.
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.
A Different Perspective
We regret to report that Coherus BioSciences shareholders are down 21% for the year. Unfortunately, that's worse than the broader market decline of 15%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 2% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Coherus BioSciences better, we need to consider many other factors. For instance, we've identified 3 warning signs for Coherus BioSciences (1 shouldn't be ignored) that you should be aware of.
We will like Coherus BioSciences better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
This month, we saw the Coherus BioSciences, Inc. (NASDAQ:CHRS) up an impressive 43%. But that doesn't change the fact that the returns over the last three years have been less than pleasing. After all, the share price is down 46% in the last three years, significantly under-performing the market.
這個月,我們看到了 科赫盧斯生物科學股份有限公司 (納斯達克:CHRS) 上升了令人印象深刻的 43%。但是,這並不能改變這一事實,即過去三年的回報率低於令人愉悅。畢竟,過去三年股價下跌了 46%,市場表現顯著不佳。
While the last three years has been tough for Coherus BioSciences shareholders, this past week has shown signs of promise. So let's look at the longer term fundamentals and see if they've been the driver of the negative returns.
儘管過去三年對 Coherus BioSciences 股東來說一直很艱難,但過去一周顯示出了承諾的跡象。因此,讓我們看看長期的基本面,看看它們是否已經成為負回報的驅動力。
See our latest analysis for Coherus BioSciences
查看我們關於科赫盧斯生物科學的最新分析
Coherus BioSciences isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
Coherus BioSciences 目前尚未獲利,因此大多數分析師都希望收入增長,以了解基礎業務的增長速度。一般來說,沒有利潤的公司預計每年都會增加收入,並且保持良好的收入。這是因為如果收入增長可以忽略不計,並且永遠不會賺取利潤,那麼公司很難相信一家公司將是可持續的。
Over the last three years, Coherus BioSciences' revenue dropped 10% per year. That is not a good result. The stock has disappointed holders over the last three years, falling 13%, annualized. And with no profits, and weak revenue, are you surprised? However, in this kind of situation you can sometimes find opportunity, where sentiment is negative but the company is actually making good progress.
在過去的三年中,科赫羅斯生物科技的收入每年下降了 10%。這不是一個好結果。在過去三年中,股票使持有人失望,年度化下降了 13%。而且沒有利潤,收入疲軟,您是否感到驚訝?但是,在這種情況下,您有時可以找到機會,其中情緒是負面的,但公司實際上正在取得良好進展。
The company's revenue and earnings (over time) are depicted in the image below (click to see the exact numbers).
該公司的收入和收益(隨著時間的推移)如下圖所示(點擊查看確切的數字)。
You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.
您可以在此看到其資產負債表如何隨著時間的推移而增強(或削弱) 自由 互動式圖形。
A Different Perspective
不同的角度
We regret to report that Coherus BioSciences shareholders are down 21% for the year. Unfortunately, that's worse than the broader market decline of 15%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Unfortunately, last year's performance may indicate unresolved challenges, given that it was worse than the annualised loss of 2% over the last half decade. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Coherus BioSciences better, we need to consider many other factors. For instance, we've identified 3 warning signs for Coherus BioSciences (1 shouldn't be ignored) that you should be aware of.
我們很遺憾地報告,科赫羅斯生物科學股東今年下跌了 21%。不幸的是,這比 15% 更廣泛的市場下跌更糟糕。但是,可能僅僅是股價受到更廣泛的市場抖動的影響。如果有很好的機會,可能值得關注基本面。不幸的是,去年的表現可能表明尚未解決的挑戰,因為它比過去半年的年度化虧損 2% 更糟糕。一般來說,長期股價疲軟可能是一個不好的跡象,儘管逆勢投資者可能希望研究股票以希望轉變。跟踪長期的股價表現總是很有趣。但是要更好地了解 Coherus 生物科學,我們需要考慮許多其他因素。例如,我們已經確定 科赫羅斯生物科學的 3 個警告標誌 (1 不應該被忽略),你應該知道。
We will like Coherus BioSciences better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
如果我們看到一些大的內部購買,我們會更喜歡 Coherus 生物科學。在我們等待的時候,看看這個 自由 成長中的公司名單,擁有相當大的,最近的內部購買。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.
請注意,本文中引用的市場回報反映了當前在美國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?關注內容? 取得聯繫 直接與我們聯繫。 或者,通過電子郵件發送電子郵件給編輯團隊。
這篇文章由簡單牆聖是一般性質. 我們僅使用公正的方法,根據歷史數據和分析師預測提供評論,我們的文章並不打算作為財務建議。 它並不構成購買或出售任何股票的建議,也不會考慮您的目標或您的財務狀況。我們的目標是為您帶來由基本數據驅動的長期集中分析。請注意,我們的分析可能不會考慮最新的價格敏感公司公告或定性材料。簡易華街在提及的任何股票中都沒有倉位。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧